このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder (SEARCH)

2021年1月25日 更新者:Sarah Kattakuzhy、University of Maryland, Baltimore
This is a double blind, placebo controlled, randomized trial to evaluate the safety and preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid agonist therapy. Patients will be randomized to two arms: (1) ANS-6637 for three months vs (2) Placebo for three months. Subjects will subsequently be followed for an additional one month post treatment.

調査の概要

状態

引きこもった

詳細な説明

This is a double blind, placebo controlled, randomized trial to evaluate the safety and preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid agonist therapy. At screening, after providing consent, participants will be evaluated to ensure criteria for opioid use disorder by DSM V criteria is met, and whether the subject is receiving opioid agonist therapy will be determined. Participants will undergo a medical evaluation (including medical history, laboratory tests and EKG evaluation) to establish baseline medical and psychiatric diagnosis in order to ensure safety of participation. Once enrollment criteria are met, patients will be randomized in a blinded fashion to ANS-6637 or placebo, stratified by site and form of opioid agonist therapy. On Day 0, patients will be initiated on ANS-6637 vs. placebo according to randomization group. Subjects will be seen twice per week for two weeks, followed by weekly for two weeks, and then monthly for two months.

研究の種類

介入

段階

  • フェーズ2

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Must have the ability to understand and must personally sign a written informed consent form, which must be obtained prior to initiation of study procedures.
  • Must be between 18 and 65 years of age, inclusive.
  • Must have the diagnosis of opioid use disorder by DSM (Diagnostic and Statistical Manual of Mental Disorders) V criteria of at least mild severity
  • Must have a total score of 9 or greater (out of a total of 30) on the Opioid Craving Scale at screening
  • If on opioid agonist therapy, must be on Opioid Agonist Therapy (OAT) medication for a minimum of six months prior to screening.
  • If on medication for depression or anxiety, must be on a stable dose for a minimum of two months prior to screening.
  • Must be able to take oral medication and be willing to adhere to the medication regimen
  • Must agree to utilize the "AI Cure" platform, either on their personal phone or on a supplied device, for both daily video adherence monitoring as well as daily questionnaires for the entire study duration.
  • Male subjects must refrain from sperm donation throughout the study period, and continuing for at least 90 days following the last dose of study drug.
  • Subjects must refrain from blood donation throughout the study period, and continuing for at least 30 days following the last dose of study drug.
  • Must be willing to comply with contraception guidelines: The fetal risks associated with ANS-6637 are not known, but pre-clinical animal data demonstrate some risk. Subjects must agree not to become pregnant or impregnate a female. Females of childbearing potential must have a pregnancy test at screening and baseline (Day 0). If pregnancy occurs or is suspected to occur, study staff must be notified immediately. For the duration of the study, subjects or female partners of childbearing potential must use one of the following, unless she is surgically sterile, post-menopausal, or partner is surgically sterile: oral contraceptives (OCP), contraceptive sponge, patch double barrier (diaphragm + spermicide or condom + spermicide), intrauterine device (IUD), etonogestrel implant, injection, hormonal vaginal contraceptive ring or complete abstinence
  • Must be willing and able to comply with all study requirements and plan to attend all clinic visits.

Exclusion Criteria:

A subject will be ineligible for this study if 1 or more of the following criteria are met:

  • Clinically significant AND grade 2 or higher abnormal laboratory values at screening, as determined by principal investigator
  • Aspartate transaminase (AST) or Alanine transaminase (ALT) > 2.5 x upper limit of normal or total bilirubin > 1.6 x the upper limit of normal
  • Creatinine clearance < 60 mL/min/1.73m2 by Chronic kidney disease (CKD)-Epidemiology Collaboration (EPI) Score.
  • Personal or family history of Parkinson's Disease
  • Diagnosed major depression AND with current self-reported depression episode
  • Diagnosed generalized anxiety disorder AND with current self-reported uncontrolled anxiety
  • Current self-reported suicidal ideation
  • Diagnosed liver disease, including untreated chronic Hepatitis C (defined as detectable Hepatitis C RNA), Hepatitis B (defined as positive HBsAg), and/or cirrhosis (defined as Fibrosis (FIB)-4 > 3.25 AND confirmed by Fibroscan or Fibrosure)
  • Diagnosed Human Immunodeficiency Virus (HIV) AND detectable viral load > 40 copies/mL
  • Diagnosed moderate or serious dementia Taking any of the following medications in the last 6 months: dopamine agonist, dopamine antagonist, anti-psychotic, anti-convulsant (except for benzodiazepines and gabapentin) or barbiturate
  • Inability to obtain venous access for sample collection.
  • Had a prior history of any severe adverse reactions to ethanol [e.g., flushing (noticeable redness of the neck or throat) and/or increased heart rate (subject reports sensation of increased heart rate or palpitations) after drinking alcohol].
  • Known hypersensitivity to formulation excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc.
  • Have previously participated in an investigational trial involving administration of any investigational compound within 30 days prior to screening
  • Have any unresolved legal issues that could jeopardize continuation or completion of the study, at the discretion of the principal investigator
  • Have any serious or active medical, surgical, or psychiatric conditions which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol.
  • Are unable to comply with study requirements

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:ANS-6637
ANS-6637 600mg once daily for 12 weeks
White, oblong 300 mg tablet
プラセボコンパレーター:Placebo arm
Placebo 600 mg once daily for 12 weeks
White, oblong 300 mg tablet

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Grade 3-4 events, Grade 2 Significant event
時間枠:16 weeks
The number of Grade 3-4 adverse events, as defined by the Division of AIDS (DAIDS) Toxicity Table Version 2.1, July, 2017 as well as the number of Grade 2 events requiring medication interruption or deemed clinically significant by a study investigator
16 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Urine Drug Screen
時間枠:16 weeks
Percentage opioid free period by urine drug screen
16 weeks
Opioid Craving
時間枠:16 weeks
Opioid craving will be assessed using the Opioid Craving scale questionnaire. The questionnaire consists of three questions and each of these questions has a minimum value of 0 and a maximum value 10. A score of 0 on each question is the best outcome; a score of 10 on each question is the worst outcome.
16 weeks
Opioid Agonist Therapy (OAT) concentration
時間枠:16 weeks
Serum concentration of buprenorphine or methadone
16 weeks
Self reported description of drug use (Self-reported frequency/quantity/mode of opioid use, self-reported use of other drugs, overdose and overdose death)
時間枠:16 weeks
Self-reported frequency/quantity/mode of opioid use as well as self-reported use of other drugs will be gathered using the Drug Use Survey. Subjects will indicate frequency of opioid use by documenting the number of times they used an opioid during a given day. The quantity of opioids used will be determined by the dollar amount of opioids the subject reports they have consumed during that day. Subjects will also report mode of opioid use by indicating whether they are using opioids via injection, skin popping, snorting or oral. The Drug Use Survey will also ask subjects to report incidence of use of non-opioid substances. Incidence of overdose will be captured with the Naloxone questionnaire which asks, "since you last visit, have you experienced an overdose?". Incidence of overdose death will measured by the number of medical examiner confirmed deaths of study participants with cause of death listed as "overdose related to an opioid".
16 weeks

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in Darke HIV Risk Taking Behavior Survey Score
時間枠:16 weeks
The Darke HIV Risk Taking Behavior Questionnaire will be administered to assess subject's self-reported risk taking behaviors. Total scores on the test range from 0 to 55, with higher scores indicating a greater degree of risk-taking behavior.
16 weeks
Change in HIV Test Result
時間枠:16 weeks
An HIV test (fourth generation antigen/antibody test) will be administered and the results are reported as either positive or negative.
16 weeks
Change in Hepatitis C (HCV) RNA result
時間枠:16 weeks
A Hepatitis C (HCV) RNA test will be administered. This test measures the quantity of detectable RNA which is measured in IU/ml.
16 weeks
Change in appetite
時間枠:16 weeks
Self reported changes in appetite will be captured by the Adverse Event Survey. The survey will ask, "since your last visit, have you had an increase in your appetite or a decrease in your appetite?".
16 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Sarah Kattakuzhy, MD、Institute of Human Virology at the University of Maryland

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (予想される)

2021年1月1日

一次修了 (実際)

2021年1月12日

研究の完了 (実際)

2021年1月12日

試験登録日

最初に提出

2019年11月5日

QC基準を満たした最初の提出物

2019年11月16日

最初の投稿 (実際)

2019年11月19日

学習記録の更新

投稿された最後の更新 (実際)

2021年1月28日

QC基準を満たした最後の更新が送信されました

2021年1月25日

最終確認日

2021年1月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • HP-00088649

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The investigator will share de-identified data with approved outside collaborators under appropriate agreements, at the time of publication or shortly thereafter.

IPD 共有時間枠

Data will be available at the time of publication or shortly thereafter, and will be kept indefinitely.

IPD 共有アクセス基準

Will be determined by Principal Investigator

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する